Please assess the completion status of the following clinical trial:

Trial Title: Histamine H2 Antagonism as Adjuvant Therapy in Treatment Resistant Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of schizophrenia assessed by SCID-I (DSM-IV) as well as RDC-criteria~* Patient record mention of schizophrenia (ICD-10) at least 5 years previously~* Disability pension due to psychiatric disorder~* At least 3 points on the CGI scale~Exclusion Criteria:~* Epilepsy or a history of unclear seizures~* Stroke~* Parkinson's disease~* AIDS~* Substance addiction or abuse within 3 months prior to enrolment.~* Individuals who are deemed at risk for aggressive behavior or suicide by their clinician~* Pregnant and breast-feeding subjects~* Serious unstable physical illness~* Persons who have been deemed legally incapacitated according to Finnish law (Laki holhoustoimesta 1.4.1999/442, 3. luku, 18 §)~* Individuals who use H2-antagonists as prescribed by a physician~* Known allergy to famotidine or any other component of the Pepcidin® 40 mg tablet~* Glomerular Filtration Rate (GFR) according to the Cockcroft-Gault formula \< 30 ml/min

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- famotidine (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).